Product
vilobelimab
Name
GOHIBIC
INN Name
vilobelimab
FDA Approved
Yes
2 clinical trials
1 organization
1 indication
1 document
Indication
Pyoderma GangrenosumClinical trial
Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)Status: Completed, Estimated PCD: 2022-01-03
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma GangrenosumStatus: Recruiting, Estimated PCD: 2026-02-13
Document
DailyMed Label: GOHIBICOrganization
InflaRx GmbH